- UHRA Home
- University of Hertfordshire
- Browsing University of Hertfordshire by Author
Browsing University of Hertfordshire by Author "Smith, L. A."
Now showing items 1-4 of 4
-
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates
Iravani, Mahmoud M.; Jackson, M. J.; Kuoppamaki, M.; Smith, L. A.; Jenner, P. (2003-10-08)Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of L-3,4-dihydroxyphenylalanine (L-DOPA) while suppressing dyskinesia in a single patient with Parkinson's disease (PD). The clinical basis ... -
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction
Stockwell, K. A.; Scheller, D.; Rose, S.; Jackson, M. J.; Tayarani-Binazir, K.; Iravani, Mahmoud M.; Smith, L. A.; Olanow, C. W.; Jenner, P. (2009-10)Rotigotine is a novel, non-ergoline dopamine D-3/D-2/D-1-receptor agonist for the treatment of Parkinson's disease that can be Continuously delivered by the transdermal route to provide stable plasma levels. Continuous ... -
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets
Stockwell, K. A.; Scheller, D. K. A.; Smith, L. A.; Rose, S.; Iravani, Mahmoud M.; Jackson, M. J.; Jenner, P. (2010-01)We previously showed that continuous infusion of rotigotine resulted in less dyskinesia than repeated pulsatile rotigotine administration or repeated oral administration Of L-DOPA in MPTP-treated marmosets. Now we investigate ... -
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets
Iravani, Mahmoud M.; Syed, E.; Jackson, M. J.; Johnston, L. C.; Smith, L. A.; Jenner, P. (2005-02)Standard MPTP treatment regimens in primates result in > 85% destruction of nigral dopaminergic neurons and the onset of marked motor deficits that respond to known symptomatic treatments for Parkinson's disease (PD). The ...